Trials / Not Yet Recruiting
Not Yet RecruitingNCT07389031
Maralixibat for Intrahepatic Cholestasis of Pregnancy
Maralixibat for the trEatment of inTrAhePatic cHOlestasis of pRegnancy (METAPHOR)
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- Sponsor
- Imperial College London · Academic / Other
- Sex
- Female
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
An open label phase 2a/b trial of maralixibat in patients with Intrahepatic Cholestasis of Pregnancy (ICP) and elevated serum bile acid concentrations (sBA) to evaluate safety and tolerability
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Maralixibat | Oral solution, dose-titrated. Maralixibat is an ileal bile acid transporter (IBAT) inhibitor. |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2028-03-31
- Completion
- 2028-03-31
- First posted
- 2026-02-05
- Last updated
- 2026-02-05
Locations
2 sites across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07389031. Inclusion in this directory is not an endorsement.